Jardiance (Empagliflozin) History and Development: From SGLT2 Discovery to Heart Failure Approval

The direct answer

Jardiance (empagliflozin) is not a single-indication diabetes drug anymore. It carries FDA-approved indications in type 2 diabetes, cardiovascular death reduction in adults with type 2 diabetes and established cardiovascular disease, heart failure across the ejection fraction spectrum, and chronic kidney disease at risk of progression. Each of these indications rests on a different pivotal trial and a different patient population, so "does Jardiance help with X" depends heavily on which X you mean. The mechanism proposed to explain the cardiovascular and renal benefits (volume reduction, restored tubuloglomerular feedback, a shift toward ketone-based myocardial fuel use) is plausible and consistent across trials, but the field has not settled on a single confirmed causal pathway, and mediation analyses are observational rather than definitive.

How SGLT2 inhibition became a drug target

The biological idea behind empagliflozin predates the drug by more than a century. Phlorizin, a compound isolated from apple tree bark in the 1800s, was known to block glucose reabsorption in the kidney and cause glucosuria, but it inhibited both SGLT1 (found in the intestine) and SGLT2 (found in the kidney), which caused diarrhea and made it unsuitable as an oral medicine. It remained a research tool rather than a therapy for a long time.

The renewed interest in SGLT2 as a selective target followed molecular identification of the two distinct sodium-glucose cotransporters. SGLT2, expressed mainly in the proximal tubule of the kidney, accounts for most of the kidney's glucose reabsorption. A natural human model supported the concept: people with familial renal glucosuria, caused by loss-of-function mutations in the gene encoding SGLT2, excrete glucose in their urine but are otherwise generally healthy. This suggested that a medicine selectively blocking SGLT2 could lower blood glucose through an insulin-independent route without the hypoglycemia risk associated with sulfonylureas or insulin. Multiple companies, including Boehringer Ingelheim, began medicinal chemistry programs aimed at a selective, orally bioavailable SGLT2 inhibitor starting in the early 2000s.

A structural change was central to making this work as an oral drug: replacing phlorizin's O-glucoside chemical backbone, which intestinal enzymes break down before it reaches the bloodstream, with a C-glucoside backbone that resists that breakdown. This is described in the medicinal chemistry literature on this drug class generally; the exact potency and selectivity figures reported for empagliflozin specifically (commonly cited as several-thousand-fold selectivity for SGLT2 over SGLT1) should be confirmed against Boehringer Ingelheim's original pharmacology publications before being repeated as precise numbers.

In 2010, Boehringer Ingelheim and Eli Lilly formed an alliance to co-develop and co-commercialize empagliflozin, along with the DPP-4 inhibitor linagliptin. That partnership combined Boehringer's discovery pipeline with Lilly's commercial infrastructure in diabetes care.

The original approval: type 2 diabetes (2014)

Boehringer Ingelheim's Phase III program for empagliflozin tested the drug as monotherapy and in combination with metformin, sulfonylureas, and pioglitazone in adults with type 2 diabetes. Across these trials, empagliflozin produced meaningful reductions in HbA1c compared with placebo, along with modest reductions in body weight and blood pressure, and hypoglycemia rates similar to placebo when not combined with a sulfonylurea or insulin. The specific numeric effect sizes commonly cited for these trials (for example, an HbA1c reduction near 0.6 to 0.7 percentage points) are broadly consistent with what has been published for this drug class, but readers should treat any single decimal figure as approximate pending confirmation against the labeled prescribing information or the original trial report.

On August 1, 2014, the FDA approved Jardiance (empagliflozin) tablets, at 10 mg and 25 mg, as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes, according to the FDA's regulatory approval record. This is a directly verifiable regulatory fact and the most stable claim in this article.

EMPA-REG OUTCOME and the cardiovascular death label

Before 2015, an FDA guidance document from 2008 required manufacturers of new diabetes drugs to conduct cardiovascular outcome trials, largely to rule out cardiovascular harm rather than to prove benefit, per longstanding FDA regulatory guidance on this topic. EMPA-REG OUTCOME was the cardiovascular outcomes trial run for empagliflozin. It enrolled adults with type 2 diabetes and established cardiovascular disease and compared empagliflozin against placebo added to standard care, with a composite primary endpoint of cardiovascular death, nonfatal heart attack, or nonfatal stroke.

The trial, published in the New England Journal of Medicine in 2015, reported a reduction in the composite cardiovascular endpoint and, notably, a substantial relative reduction in cardiovascular death specifically, along with a reduction in heart failure hospitalization. This was widely reported at the time as the first instance of a glucose-lowering drug demonstrating a cardiovascular mortality benefit in a randomized trial. The precise hazard ratios and confidence intervals commonly quoted for this trial should be checked against the original NEJM publication before being cited as exact figures in a clinical context; this draft intentionally avoids repeating unverified decimal statistics as though they were confirmed.

Based on this trial, the FDA added a new indication in December 2016: reduction of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, according to the FDA's regulatory approval record. This made Jardiance the first diabetes medicine to carry a cardiovascular death reduction claim on its FDA label, a genuinely notable regulatory milestone independent of the exact trial numbers.

An earlier draft of this article included direct quotations attributed to a trial investigator and to an ADA consensus document. Those quotations could not be verified against a locatable, checkable source and have been removed rather than repeated. If a verified quotation exists in the original NEJM paper, the ADA Standards of Care, or a recorded conference presentation, an editor should reinsert it with a direct citation rather than relying on this draft's earlier wording.

Why the benefit appeared quickly: what is established and what is still a hypothesis

One frequently cited observation is that cardiovascular death curves in EMPA-REG OUTCOME separated within the first few months of treatment, earlier than glucose lowering alone would be expected to produce a mortality effect. This observation is plausible and has driven a body of mechanistic research, but it should be treated as an interesting pattern rather than a proven causal explanation.

What is established: SGLT2 inhibitors, including empagliflozin, produce measurable diuretic and natriuretic effects, lower blood pressure modestly, and reduce plasma volume. These physiological effects are documented in pharmacology and short-term clinical studies.

What is plausible but not proven: That plasma volume contraction, restored tubuloglomerular feedback (reducing intraglomerular pressure in the kidney), and a shift toward ketone body use by the heart are the specific mechanisms responsible for the mortality and heart failure benefits seen in outcome trials. These mechanisms are supported by physiological studies and post hoc mediation analyses, which are hypothesis-generating rather than definitive proof of causation.

What is not established: A single unified mechanism explaining the full magnitude of cardiovascular and renal benefit across every trial and population. Researchers still debate the relative contribution of each proposed pathway.

Heart failure: EMPEROR-Reduced and EMPEROR-Preserved

Following the heart failure hospitalization signal seen in EMPA-REG OUTCOME, Boehringer Ingelheim and Lilly ran two dedicated heart failure trials. EMPEROR-Reduced enrolled patients with heart failure and a reduced ejection fraction (with or without diabetes) and reported a reduction in the combined risk of cardiovascular death or heart failure hospitalization. EMPEROR-Preserved enrolled patients with heart failure and a preserved ejection fraction, a population in which prior heart failure drugs had generally failed to show benefit, and also reported a positive result on its composite endpoint. Both trials found that the benefit did not depend on whether the patient had diabetes, which supported the idea that the cardiovascular effects of empagliflozin are independent of its glucose-lowering action.

In 2022, the FDA approved empagliflozin for heart failure across the ejection fraction spectrum, extending its use beyond patients with diabetes, according to the FDA's regulatory approval record. As with the diabetes and cardiovascular trials above, the specific hazard ratios reported for EMPEROR-Reduced and EMPEROR-Preserved should be verified against the original trial publications before being used as exact figures.

Chronic kidney disease: EMPA-KIDNEY

EMPA-KIDNEY tested empagliflozin against placebo in a broad population of people with chronic kidney disease, including both those with and without diabetes, across a range of kidney function levels. The trial was stopped early because an independent monitoring process found clear evidence of benefit on its primary composite endpoint of kidney disease progression or cardiovascular death. This result supported an FDA approval in 2023 for reducing the risk of further kidney function decline in adults with chronic kidney disease at risk of progression (FDA drug safety and availability page). Kidney disease treatment guidelines from major nephrology bodies have since incorporated SGLT2 inhibitors as a recommended part of care for eligible patients with CKD; readers should confirm the current guideline wording with their own clinician, since guideline language and eligibility thresholds are periodically revised.

What this means if you or someone you know takes Jardiance

Empagliflozin's approved uses now span diabetes, cardiovascular risk reduction, heart failure, and chronic kidney disease, but a person's actual reason for taking it, their kidney function, their volume status, and their risk of ketoacidosis or genital infections all affect whether the drug is appropriate and how it should be monitored. This is not a page for individualized dosing guidance. Anyone starting or adjusting empagliflozin should do so under a clinician's direction, and anyone who develops symptoms of diabetic ketoacidosis (nausea, vomiting, abdominal pain, unusual fatigue, difficulty breathing) while taking an SGLT2 inhibitor, with or without high blood glucose readings, should seek urgent medical care rather than waiting for a routine appointment.

Decision framework: matching the evidence to the reason someone takes Jardiance

The same drug carries different strength and type of evidence depending on the indication. This framework is meant to help a reader (or a clinician explaining the drug to a patient) locate which evidence tier applies to their specific situation, since "Jardiance works" is not a single claim.

Next step for a reader trying to decide whether a claim about Jardiance applies to them: identify which row above matches their actual clinical reason for taking (or being offered) the drug, then ask their prescriber which trial population that recommendation was based on and whether their own kidney function, diabetes status, and cardiovascular history match that population.

Commercial and access context

Jardiance has been reported as one of the highest-selling drugs in the SGLT2 inhibitor class in company financial disclosures, and combination products (Synjardy with metformin, Glyxambi with linagliptin) extend the same molecule into fixed-dose formulations. Specific annual sales figures change year to year and should be sourced from current company or public financial filings rather than repeated from an earlier draft of this page. As of the most recent information available to this draft, no generic version of empagliflozin is marketed in the United States, and this status can change; readers checking generic availability should confirm the current date-stamped status with the FDA's Orange Book or a pharmacist rather than relying on a fixed year cited here.

Ongoing research

Additional trials have examined empagliflozin after acute heart attack and its effect on exercise capacity in heart failure, and research continues into other potential uses such as metabolic-dysfunction-associated steatohepatitis, atrial fibrillation, and gout. These represent active investigational areas, not approved indications, and any specific numeric results from these newer trials should be verified against the primary publication before being treated as established.

Common questions

References

1. U.S. Food and Drug Administration. FDA approval record for Jardiance (empagliflozin), type 2 diabetes indication. August 1, 2014.
2. U.S. Food and Drug Administration. FDA approval record for Jardiance (empagliflozin), cardiovascular death reduction indication. December 2, 2016.
3. U.S. Food and Drug Administration. Guidance for industry: diabetes mellitus, evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. December 2008.
4. U.S. Food and Drug Administration. Drug safety and availability. https://www.fda.gov/drugs/drug-safety-and-availability
5. U.S. Food and Drug Administration. FDA approval record for Jardiance (empagliflozin), heart failure indication expansion, 2022.
6. Boehringer Ingelheim. Corporate site, for general company and product background. https://www.boehringer-ingelheim.com

Editorial flag for reviewers: The trial names EMPA-REG OUTCOME, EMPEROR-Reduced, EMPEROR-Preserved, and EMPA-KIDNEY, and their general findings, are consistent with widely reported outcomes for this drug class. However, this draft intentionally does not cite specific PubMed identifiers or repeat precise hazard ratios, confidence intervals, or sales figures from the prior version of this page, because those identifiers could not be independently confirmed as pointing to the correct paper. Before publication, a reviewer with database access should locate and re-attach verified PMID or DOI links for each trial and confirm or correct the numeric results described in general terms above. The two direct quotations in the prior draft (attributed to a trial investigator and to an ADA document) were removed rather than retained, since neither could be confirmed against a locatable source.